GI-DLBCL has a significantly reduced frequency of CD79B and MYD88 mutations compared with nodal DLBCL and extranodal DLBCL of immune-privileged sites (9–11). The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.